Good news that Lu-177 Infusion treatment is now available to certain PCa patients. Commercial name is PLUVICTO. ..For “adult patients with PSMA-positive metastatic castration resistant prostate cancer who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy.”
My question is: what will be required for FDA approval for earlier stage patients, namely, those who have failed first line treatment (surgery, radiation), but are still castration-sensitive. Will there have to be phase I, phase II and phase III trials?
It’s crazy that this treatment is available in a number of other countries, and has been for a number of years.